Access To Medicines And The Trips Agreement What Next For Sub-Saharan Africa

The World Health Organization (WHO) has taken several steps to address the potential adverse health effects of protection. In particular, the 61st World Health Assembly adopted Resolution 61.21 in 2008, which endorsed the Global Strategy and Action Plan for Public Health, Innovation and Intellectual Property13. This comprehensive strategy aims in particular to improve the provision and access to health devices and medical devices by effectively removing barriers to access. The comprehensive strategy was adopted following an 18-month session of the WHO Intergovernmental Working Group on Public Health.14 Recent WHO actions include an in-depth study on access to medical technologies and innovation. implemented in cooperation with the World Intellectual Property Organization (WIPO) and the World Trade Organization (WTO) 15, as well as the publication of its Project Zero of the Global Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020.16 WIPO has low- and low-income countries 17 Despite obvious restrictions and numerous restrictions imposed by the decision reviewed by the decision reviewed , countries that need to acquire patented medicines should test the viability of the system. In accordance with the Doha Declaration on TRIPS and Public Health, the decision should be interpreted in such a way as to increase the supply of medicines to poor countries. It is also necessary, on the basis of an amendment to the TRIPS agreement, to find a lasting solution to the problem affecting countries with or are not limited production capacity in this area. Such a change should be based on a simpler and simpler approach26, which provides economic incentives for the effectiveness of the solution. It is also important to note that the system in paragraph 6 appears to be based on the assumption that a patent holder is legitimized to prevent access to products under his control, even if there are compelling humanitarian reasons.